ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer [1]

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 4127-

  Marsh, Sharon ^a   King, Cristi R ^a   McLeod, Howard L ^a   Paul, Jim ^b   Gifford, Gillian ^b   Brown, Robert ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GENOMIC DNA; PACLITAXEL; TUMOR MARKER;

ABCB1 GENE; ABSENCE OF SIDE EFFECTS; BLOOD TOXICITY; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; GASTROINTESTINAL TOXICITY; GENE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; LUNG CANCER; NEUROTOXICITY; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; RADIATION RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PREDICTIVE VALUE OF TESTS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 33746090916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0461     Document Type: Letter

References (4)

1. Green H, Söderkvist P, Rosenberg P, Horvath G, Peterson C. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12:854-9.
2. Marsh S. Taxane pharmacogenetics. Personalized Med 2006;3:33-43.
3. Marsh S, Somlo G, McLeod HL, et al. Pharmacogenetic analysis of paclitaxel in breast cancer. Proc Am Soc Clin Oncol 2005;23:206.
4. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.